CORAL GABLES, FL/ ACCESSWIRE / March 27, 2019 / The future of the biotech stock is predicated on the belief that the biotech sector is aptly prepared to develop innovative treatment options for patients in need. Medical experts and care professionals are faced with an increasing global population and discoveries of infectious diseases on a near-daily basis. Through the use of machine learning, data analytics, genome sequencing, and other biotechnological advancements, companies in the biotech sector are working hard to improve the quality of life for consumers. Considering the innovation and impressive progress being made in biotech, investors looking for potential opportunities could benefit from keeping watch. Premier Health Group (PHGRF) (PHGI), Amyris Inc (AMRS), Jaguar Health Inc (JAGX), and AVEO Pharmaceuticals Inc (AVEO) are 4 healthcare companies making biotech companies making moves on Wednesday.

Premier Health Group (PHGRF) (PHGI) is a company determined to develop innovative approaches that combine human skill-based expertise with state-of-the-art technologies to offer to their patients the best possible treatment solutions and primary care. At a time where consumers depend on healthcare companies to provide quality care solutions, Premier Health is prepared to meet the needs of its patients.

Premier Health Group (PHGRF) (PHGI) made headlines today when the Company announced that it has initiated integration of CB2 Insights’ medical cannabis Clinical Decision Support tool. Per the details of the initiative, the agreement will give the more than 4600 physicians and healthcare practitioners using Premier Health’s Juno EMR platform access to the industry’s only medical cannabis-specific CDS tool. CB2 Insights’ CDS tool is designed to help incorporate medical cannabis into their patient’s treatment plans.

Following the announcement, Dr. Essam Hamza, CEO of Premier Health Group (PHGRF) (PHGI), stated, “we are dedicated to finding new ways to create value for our physician network. We continue to receive multiple requests from physicians who ask about how best to incorporate medical cannabis into their clinics. This agreement with CB2 will provide us a robust, validated tool to give our physicians and healthcare practitioners a safe and secure way to qualify, educate and where appropriate, prescribe medical cannabis to their patients in a compliant manner.”

For More Information On Premier Health Group, Click Here

Amyris Inc (AMRS), a leader in the development and production of sustainable ingredients for the biotech sector, today announced that the Company’s management team will be presenting at the Paradigm Capital Biosynthesis Conference on April 15 in Toronto. Amyris believes that with its proven commercial history and leading technology platform that it is well suited to leverage development and commercialization of high-purity cannabinoids at significantly reduced cost through fermentation.

John Melo, President, and CEO of Amyris said, “we’re pleased to share our strategy and progress for cannabis at this conference. We have now completed in our labs the technical performance requirements for our first major milestone for our CBD collaboration and share the excitement of our partner and their commitment to market leadership by enabling some of the world’s leading brands to improve the health and wellness of consumers.”

For More Information On Amyris Inc, Click Here

Jaguar Health Inc (JAGX) saw impressive gains in the market on Wednesday, with its shares soaring 30.19%, trading at $0.31 per share in the early afternoon. The commercial stage pharmaceutical company last week announced that it had completed the filing with the U.S. Food & Drug Administration’s Center for Veterinary Medicine of the Chemistry, Manufacturing, and Controls Technical Section in support of the Company’s application for conditional approval of Canalevia™ for the treatment of chemotherapy-induced diarrhea in dogs.

Lisa Conte, President, and CEO of Jaguar commented, “since our July 2017 merger with Napo Pharmaceuticals, as previously announced, Jaguar’s human portfolio has been, and continues to be, our core focus. However, CID is an interesting model for human product performance and is being pursued as our first prescription indication for animal health. We believe there is an important unmet medical need for the treatment of CID in dogs.”

For More Information On Jaguar Health Inc, Click Here

AVEO Oncology Inc (AVEO) earlier this month reported financial results for the full year ended December 31, 2018, and provided a business update. Last month, the Company presented topline results from the TIVO-3 trial, AVEO’s Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in 350 subjects with refractory advanced or metastatic renal cell carcinoma at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium.

Following the Company’s corporate update, Michael Bailey, President and CEO of AVEO, said, “we continue to believe that there is a significant potential commercial opportunity for an active and well-tolerated therapy within the third plus line of therapy, particularly one that demonstrated activity in a highly refractory patient population that has received prior PD-1 treatment. We are hopeful that the positive PFS outcomes from TIVO-3 translate into an improved overall survival hazard ratio and look forward to reporting a more mature interim OS outcome in the fourth quarter of 2019.”

For More Information on AVEO Pharmaceuticals Inc, Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to June 1, 2019. As of 3/26/2019 Midam has been compensated an additional $100,000 by Premier Health Group for additional coverage without further extended coverage duration. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the “500,000” shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.

Contact Information:

[email protected]

SOURCE: StockPrice.com